Bristol-Myers Squibb (NYSE:BMY) recently announced a significant partnership with BioNTech SE to co-develop and co-commercialize the bispecific antibody BNT327, targeting multiple solid tumor types. This collaboration,

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

By Michael Erman and Ludwig Burger (Reuters) -Bristol Myers Squibb has agreed to pay up to $11.1 billion in a partnership with Germany's BioNTech to develop the latter's next-generation cancer immunotherapy that could take on rival Merck & Co's best-selling drug Keytruda.